New hope for rare bone cancer: targeted drug AG-120 shows promise

NCT ID NCT04278781

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 25 times

Summary

This study tests a drug called AG-120 in people with a rare bone cancer (chondrosarcoma) that has a specific genetic change (IDH1 mutation). The goal is to see if the drug can stop or slow the cancer from growing. The study includes 6 adults with advanced or recurrent disease who have not responded to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University (Specimen Analysis Only)

    New York, New York, 10032, United States

  • Johns Hopkins Hospital (Data Collection Only)

    Baltimore, Maryland, 21287, United States

  • MD Anderson Cancer Center (Data Collection Only)

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • The Ohio State University (Data Collection Only)

    Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.